harnessing novel t cell systems to extend the promise of immunotherapy
Company profile
Ticker
TCRX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
TScan Securities Corporation ...
IRS number
825282075
TCRX stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
17 Apr 24
8-K
TScan Therapeutics Announces Launch of $125 million Proposed
17 Apr 24
FWP
Free writing prospectus
17 Apr 24
424B5
Prospectus supplement for primary offering
16 Apr 24
8-K
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
16 Apr 24
EFFECT
Notice of effectiveness
15 Apr 24
10-K/A
2023 FY
Annual report (amended)
10 Apr 24
8-K
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert
8 Apr 24
S-3
Shelf registration
6 Mar 24
S-8
Registration of securities for employees
6 Mar 24
Latest ownership filings
SC 13D/A
BAKER BROS. ADVISORS LP
23 Apr 24
4
JULIAN BAKER
23 Apr 24
4
Weston Nichols
23 Apr 24
SC 13G/A
K2 HealthVentures Equity Trust LLC
14 Feb 24
SC 13G/A
GV 2017, L.P.
9 Feb 24
SC 13G/A
Pitango HealthTech Fund I, L.P.
8 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4
Jason Amello
2 Feb 24
3
Jason Amello
2 Feb 24
4
TIMOTHY J BARBERICH
21 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 160.22 mm | 160.22 mm | 160.22 mm | 160.22 mm | 160.22 mm | 160.22 mm |
Cash burn (monthly) | 17.88 mm | (no burn) | 8.25 mm | 7.56 mm | (no burn) | 4.47 mm |
Cash used (since last report) | 122.10 mm | n/a | 56.32 mm | 51.63 mm | n/a | 30.50 mm |
Cash remaining | 38.13 mm | n/a | 103.90 mm | 108.59 mm | n/a | 129.73 mm |
Runway (months of cash) | 2.1 | n/a | 12.6 | 14.4 | n/a | 29.0 |
Institutional ownership, Q2 2023
89.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 7 |
Closed positions | 7 |
Increased positions | 7 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 69.56 bn |
Total shares | 39.16 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lynx1 Capital Management | 5.22 mm | $13.06 bn |
EcoR1 Capital | 5.00 mm | $12.50 bn |
Biotechnology Value Fund L P | 4.41 mm | $14.08 mm |
Adage Capital Partners GP, L.L.C. | 4.00 mm | $10.00 bn |
BVF | 2.99 mm | $7.47 bn |
Baker Bros. Advisors | 2.78 mm | $6.96 bn |
K2 HealthVentures Equity Trust | 2.10 mm | $6.93 mm |
Vanguard | 1.36 mm | $3.40 bn |
Longwood Fund IV | 1.28 mm | $5.76 mm |
BLK Blackrock | 1.26 mm | $3.16 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Apr 24 | Lynx1 Capital Management | Pre-funded Warrant Common Stock | Buy | Acquire P | Yes | No | 7.1299 | 5,000,000 | 35.65 mm | 5,000,000 |
19 Apr 24 | Baker Bros. Advisors | Warrants to purchase Common Stock Common Stock | Buy | Acquire P | Yes | No | 7.1299 | 8,851,451 | 63.11 mm | 43,158,741 |
19 Apr 24 | Baker Bros. Advisors | Warrants to purchase Common Stock Common Stock | Buy | Acquire P | Yes | No | 7.1299 | 825,968 | 5.89 mm | 4,018,678 |
1 Feb 24 | Jason Amello | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 5.15 | 750,000 | 3.86 mm | 750,000 |
19 Dec 23 | Barberich Timothy J | Voting Common Stock | Buy | Acquire P | No | No | 4.9685 | 317 | 1.58 k | 67,027 |
18 Dec 23 | Barberich Timothy J | Voting Common Stock | Buy | Acquire P | No | No | 4.8866 | 28,830 | 140.88 k | 66,710 |
News
Unveiling 4 Analyst Insights On TScan Therapeutics
23 Apr 24
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $10 Price Target
23 Apr 24
TScan Therapeutics Prices Upsized $150M Public Offering 2,472,581 Common Shares At $7.13/Share
17 Apr 24
TScan Therapeutics Reports Launch Of $125M Proposed Public Offering
16 Apr 24
TScan Therapeutics Provides Update On Its Solid Tumor And Heme Malignancies Clinical Programs
16 Apr 24
Press releases
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
24 Apr 24
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
22 Apr 24
TScan Therapeutics Announces Closing of Upsized Public Offering
19 Apr 24
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
17 Apr 24
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
16 Apr 24